Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation
Bone Marrow Transplantation, Volume 48, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT (N=168) or BMT (N=216) and were treated with donor lymphocyte infusions (DLI). Univariate analysis revealed a lower probability of OS after DLI in patients relapsing after PBSCT vs BMT (66% vs 79% at 5 years, P=0.013). However, a multivariate Cox analysis did not reveal any significant impact of PBSCT as a risk factor for decreased OS for patients transplanted in first chronic phase (CP1; hazard ratio (HR) 1.036, 95% confidence interval (CI) 0.619-1.734). A statistical interaction term suggested that the impact of stem cell source on OS after DLI was different for those transplanted in advanced phases (negative impact of previous PBSCT-HR 2.176, 95% CI 0.930-5.091). In summary, the stem cell source does not affect the OS of CML patients who underwent PBSCT in CP1, relapsed and were treated with DLI. However, when the patients were transplanted in advanced phases, previous PBSCT seems to negatively affect OS after DLI compared with BMT. © 2013 Macmillan Publishers Limited All rights reserved.
Authors & Co-Authors
Basak, Grzegorz
Poland, Warsaw
Medical University of Warsaw
de Wreede, Liesbeth C.
Netherlands, Leiden
Leids Universitair Medisch Centrum
van Biezen, Anja A.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Wiktor-Jedrzejczak, Wieslaw
Poland, Warsaw
Medical University of Warsaw
Hałaburda, Kazimierz
Poland, Warsaw
Medical University of Warsaw
Schmid, Christof C.
Germany, Augsburg
Klinikum Augsburg
Schaap, Nicolaas P.M.
Netherlands, Nijmegen
Radboud University Medical Center
Dazzi, F.
United Kingdom, London
Imperial College London
Von Dem Borne, P. A.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Petersen, Eefke J.
Netherlands, Utrecht
University Medical Center Utrecht
Beelen, Dietrich Wilhelm
Germany, Essen
Universitätsklinikum Essen
Abayomi, Emmanuel Akinola
South Africa, Cape Town
Constantiaberg Medi-clinic
Volin, Liisa
Finland, Helsinki
Helsinki University Hospital
Buzyn, Agnès
France, Paris
Hôpital Necker Enfants Malades
Gürman, Günhan
Turkey, Ankara
Ankara Üniversitesi
Bunjes, Donald W.
Germany, Ulm
Universitätsklinikum Ulm
Guglielmi, C.
Italy, Rome
Sapienza Università Di Roma
Olavarría, Eduardo
Spain, Pamplona
Hospital de Navarra
de Witte, Theo J.M.
Netherlands, Nijmegen
Radboud University Medical Center
Statistics
Citations: 19
Authors: 19
Affiliations: 14
Identifiers
Doi:
10.1038/bmt.2012.234
ISSN:
02683369
e-ISSN:
14765365
Research Areas
Cancer
Environmental